Brain Scientific Inc.
BRSF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.07 | 0.28 |
| FCF Yield | -6,262.71% | -87.42% | -4.59% | -5.69% |
| EV / EBITDA | -0.28 | -2.00 | -7.87 | -16.16 |
| Quality | ||||
| ROIC | -133.81% | -93.36% | 222.25% | 5,774.30% |
| Gross Margin | 25.32% | 31.32% | 53.28% | 20.85% |
| Cash Conversion Ratio | 0.48 | 0.64 | 0.33 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.82% | -18.41% | 17.25% | 311.47% |
| Free Cash Flow Growth | -0.72% | -515.93% | -12.42% | 23.17% |
| Safety | ||||
| Net Debt / EBITDA | -0.27 | -1.19 | -0.25 | -0.64 |
| Interest Coverage | -2.67 | -15.52 | -93.96 | -29.47 |
| Efficiency | ||||
| Inventory Turnover | 1.07 | 1.25 | 0.97 | 0.00 |
| Cash Conversion Cycle | -2,107.61 | -1,886.44 | -2,940.63 | -286.05 |